Calidi Biotherapeutics, Inc. (CLDI)
Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety.
Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors.
The company was founded in 2014 and is based in San Diego, California.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 41 |
CEO | Allan J. Camaisa |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
Phone | 858-794-9600 |
Website | calidibio.com |
Stock Details
Ticker Symbol | CLDI |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001855485 |
Employer ID | 86-2967193 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Allan J. Camaisa | Chief Executive Officer and Chairman of the Board |
Wendy Pizarro Campbell Esq. | Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer and Corporate Secretary |
Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs and Interim Chief Medical Officer |
Andrew C. Jackson | Chief Financial Officer |
Dr. Amish Patel Ph.D. | Senior Vice President of Technical Operations |
Dr. David Sans M.B.A., Ph.D. | Chief Corporate Development |
Stephen Thesing | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Mar 21, 2024 | D | Notice of Exempt Offering of Securities |
Mar 18, 2024 | 8-K | Current Report |
Mar 15, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 424B3 | Prospectus |
Mar 12, 2024 | 8-K | Current Report |
Mar 1, 2024 | 424B3 | Prospectus |